Mesoblast Reports Strong Revenue Growth with Ryoncil® Adoption
I'm PortAI, I can summarize articles.
Mesoblast Limited reported a 69% increase in net sales for Ryoncil® in Q3 2025, following the assignment of a permanent J-Code by CMS. The company has onboarded 40 transplant centers and expanded coverage to over 260 million US lives. Mesoblast plans a pivotal trial for Ryoncil® in adults with severe SR-aGvHD. Despite strong revenue growth, the stock rating is a Hold with a $20.00 price target, reflecting financial performance challenges. Mesoblast focuses on allogeneic cellular medicines and has a market cap of $2.21B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments